SCHEMBL19726336

SCHEMBL19726336

CCc1cc2c(cc1CC)CC(OC(C)=O)C2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.33
DRD1 P21728 1/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ADRB2 P07550 2/20 0.32
ADRB1 P08588 2/20 0.32
SLC6A2 P23975 1/20 0.32
ADRA1D P25100 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
SLC6A4 P31645 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
DRD3 P35462 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19726332 0.89 HSD17B1 (0.36) DRD2DRD1KMT2AMEN1ALDH1A1
SCHEMBL19726331 0.82 AKT1 (0.36) DRD2KMT2ADRD3TSHR
SCHEMBL28381288 0.75 SLC6A4 (0.42) KMT2AMAPTSLC6A4
SCHEMBL30493000 0.75 FABP7 (0.50) KMT2AGABRA1GABRB2TSHRCHRM2
SCHEMBL1196934 0.75 FABP7 (0.50) KMT2AGABRA1GABRB2TSHRCHRM2
SCHEMBL30493157 0.74 PNMT (0.42)
SCHEMBL3725001 0.74 MAPT (0.51) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL16127116 0.74 PNMT (0.36) KMT2AGABRA1GABRB2TSHRMTNR1A
SCHEMBL6200513 0.74 ALDH1A1 (0.42) ALDH1A1HSD17B10
SCHEMBL1197541 0.74 PNMT (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170362161-A1 PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES OLON S.P.A. (IT) 2017-12-21 US disclosed
US-20170362161-A1 PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES OLON S.P.A. (IT) 2017-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362161-A1 PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES CYP3A5, SQLE, CYP3A4 DRD2 686/4885DRD1 880/4885KMT2A 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.